IDSA is partnering
with the American Gastroenterological Association (AGA) in a new initiative to
develop the first national registry for short- and long-term patient outcomes
associated with fecal microbiota transplantation (FMT).
Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes
of Health (NIH) is funding the new initiative, which will enable researchers to
identify potential adverse outcomes and possible safety concerns of FMT.
accumulating evidence suggests that modifying gut microbiota may promote health
or treat disease, with FMT for Clostridium
difficile infection being the first successful clinical application of this concept.
Researchers are now exploring FMT for conditions beyond C. difficile. However, the early adoption and expansion of
FMT in clinical practice has outpaced scientific study, resulting in a lack of
understanding of the potential health risks from human‐to‐human
transfer of stool. Eventually,
the data collected through the registry will provide long-term uses in
understanding how manipulation of the gut microbiota could treat disease and
promote overall health.
partners in the initiative are the Crohn’s and Colitis Foundation of America
and the North American Society for Pediatric Gastroenterology, Hepatology and
< Previous Article | Next Article >